

DOCKET NO.: CELL-0316
Application No.: 10/580,164
Preliminary Amendment - First Action Not Yet Received

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-9. (canceled)

10. (currently amended) A method for the treatment ~~and/or~~ or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity to a patient in need thereof.

11. (currently amended) The method according to claim 10, wherein the inhibitor is a small molecule ~~(NCE)~~.

12. (original) The method according to claim 10, wherein the inhibitor is a nucleic acid.

13. (currently amended) The method according to claim 10, wherein the inhibitor is an antibody or a functionally active antibody fragment or derivative ~~thereof~~.

14. (currently amended) The method according to claim 13, wherein the antibody or antibody fragment ~~thereof~~ is monoclonal, polyclonal, chimeric, ~~humanised~~ humanized or bispecific.

15. (currently amended) The method according to claim 13 ~~or claim 14 where~~ wherein the antibody fragment is a Fab, Fab', F(ab')₂, scFv or epitope binding fragment ~~thereof~~.

16. (currently amended) The method according to ~~any one of claims 13-15~~ claim 13 wherein the antibody or antibody fragment ~~thereof~~ is conjugated to one or more effector molecule(s).

17. (currently amended) The method according to ~~any one of claims 13-16~~ claim 13 ~~in which~~ wherein the antibody or antibody fragment ~~thereof~~ binds to IL-17.

DOCKET NO.: CELL-0316

Application No.: 10/580,164

Preliminary Amendment - First Action Not Yet Received

18. (currently amended) The method according to ~~any one of claims 13-16~~ claim 13 in ~~which~~ wherein the antibody or antibody fragment ~~thereof~~ binds to IL-17R.

19. (currently amended) The method according to ~~any one of claims 10-18~~ claim 10 ~~where~~ wherein the inhibitor of IL-17 activity is administered in combination with one or more other therapeutically active compounds.